期刊文献+

培美曲塞或紫杉醇联合顺铂一线治疗晚期肺腺癌的随机对照研究 被引量:5

下载PDF
导出
摘要 目的:观察培美曲塞或紫杉醇联合顺铂一线治疗晚期肺腺癌的近期疗效和毒副反应。方法:将符合入组标准的60例晚期肺腺癌患者随机分为两组,观察组30例采用培美曲塞联合顺铂治疗,对照组30例采用紫杉醇联合顺铂治疗,2个周期后评价疗效及不良反应。结果:观察组总有效率36.67%,对照组30.00%,两组比较差异无统计学意义(P>0.05)。Ⅲ~Ⅳ级血液学毒性反应发生率观察组低于对照组,差异有统计学意义(P<0.05)。结论:培美曲塞联合顺铂一线治疗晚期肺腺癌疗效与紫杉醇联合顺铂相当,血液学毒性较低。
出处 《实用医学杂志》 CAS 北大核心 2011年第17期3212-3213,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献7

  • 1Devesa S S, Bray F, Vizcano A P, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising [J]. Int J Cancer, 2005,117(2) :294-299.
  • 2D'Addario G, Pintilie M, Leighl N B, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non- small-cell lung cancer: a meta-analysis of the published literature [ J ]. J Clin Oncol, 2005,23 ( 13 ) : 2926-2936.
  • 3Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis [J]. JAMA, 2004,292(4) :470-484.
  • 4Curtin N J, Hughes A N. Pemetrexed disodium, a novel antifolate with multiple targets [J]. Lancet Oneol, 2001,2(5):298-306.
  • 5Adjei A A. Pemetrexed (ALIMTA), a novel muhitargeted antineoplastic agent [J]. Clin Cancer Res, 2004,15 (10) : 4276-4280.
  • 6Scagliotti G V, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008,26(21): 3543-3551.
  • 7GrCnberg B H, Bremnes R M, Flctten O, et al. Phase II1 study by the Norwegian lung cancer study group: pemetrexed plus earboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer [J]. J Clin Oncol, 2009, 27(19): 3217-3224.

同被引文献49

  • 1李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量:73
  • 2鲍云华,李俭杰.介绍新的实体瘤治疗反应评价标准(RECIST)[J].中国肺癌杂志,2005,8(1):77-78. 被引量:108
  • 3周爱华.培美曲塞联合顺铂与多西他赛联合顺铂治疗晚期肺腺癌的临床疗效对比[J].实用心脑肺血管病杂志,2013,21(10):132.
  • 4李进.肿瘤内科诊治策略[M]上海:上海科学技术出版社,201049-63.
  • 5Gronberg B H,Bremnes R M. Phase Ⅲ study by the Norwegian lung cancer study group:pemetrexed pluscarboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer[J].Journal of Clinical Oncology,2009,(19):3217-3224.doi:10.1200/JCO.2008.20.9114.
  • 6孙燕;石远凯.临床肿瘤内科手册[M]北京:人民卫生出版社,2009826-830.
  • 7Adjei A. Pharmacology and mechanism of action of pemetrexed[J].Clinical Lung Cancer,2004,(01):51-55.
  • 8Vogcixang N J,Rusthovcn I I,Symanowski I. Phase Ⅲ study of pemetrexed combination with cisplatin versuscisplatin alone in patients with malignant pleural mesothelioma[J].Journal of Clinical Oncology,2003,(14):2636-2644.
  • 9Scaglioti G,Parikh P,von Pawel J. Phase Ⅲ study comparing cisplatin plus gemcitahion with cisplatin plus pemetrexed in chemotherapy.naive patients with advancedstage non-small cell lung cancer[J].J Clin Gncol,2008,(21):3543-3551.doi:10.1200/JCO.2007.15.0375.
  • 10Biorn H G,Ray M B,Tore A. Phase Ⅲ study by the Norwegian lung cancer study group,pemetrexed plus carboplatin compared with gemeitabine plus carboplatin as firsrt-line chemotherapy in advanced non-small-cell lung caner[J].J Clin Gncol,2009,(19):3217-3219.

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部